Skip to content

Preauthorization Versus Prospective Audit in Antimicrobial Stewardship Program

The Impact of Preauthorization Compared to Prospective Audit on Outcome Indicators as Core Strategies of Antimicrobial Stewardship Program

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02837081
Enrollment
1060
Registered
2016-07-19
Start date
2015-12-31
Completion date
2017-03-31
Last updated
2016-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Infections

Brief summary

Antimicrobial stewardship program (ASP) is recommended to improve appropriate antimicrobial use, reduce bacterial resistance, unnecessary drug costs and enhance patient health outcomes. Two core strategies of ASP recommended as effective in guidelines are formulary restriction with drug preauthorization and prospective audit with feedback. Investigators will evaluate the effectiveness of the 2 strategies using antimicrobial utilization and patient outcomes.

Detailed description

Background: Antimicrobial stewardship program (ASP) is recommended to improve appropriate antimicrobial use, reduce bacterial resistance, unnecessary drug costs and enhance patient health outcomes. Two core strategies of ASP recommended as effective in guidelines are formulary restriction with drug preauthorization and prospective audit with feedback. Preauthorization is the current strategy used in our hospital, while most other hospitals in Taiwan and worldwide uses prospective audit with feedback. Preauthorization requires intensive manpower to maintain timeliness of antimicrobial use. This study will evaluate a policy change in strategy used for antimicrobial stewardship. Investigators will evaluate the effectiveness of the 2 strategies using antimicrobial utilization and patient outcomes. Methods: During a stepwise change in the policy of the antimicrobial stewardship program in this hospital, the study will observe the differences between two standardized core strategies (preauthorization vs prospective audit) of ASP. Hospitalized patients aged 20 and above, requiring use of restricted antimicrobials will be recruited into the study. Signing of consent forms are waived since both strategies are already proven to be effective and are widely implemented in Taiwan and worldwide. Also, the evaluation of such policy changes will not impact on patient safety or patient rights. The conduction of the study will not require contacting patients and no clinical samples will be collected. All data required for analysis will be collected via a computerized patient care system. Patient data will be protected via de-linking. Patients will be excluded if admitted at or entered the intensive care unit within 48 hours of entry, and if infectious diseases consultation had been requested. Eligible patients will be randomized to either preauthorization, which is the current practice in the hospital; or prospective audit, that will be done at 48-72 hours after prescription, as is the current practice in other hospitals in Taiwan and worldwide. Managing physicians are not obligated to follow our advice and the investigators will not intervene in their management decisions. Primary outcomes include antimicrobial utilization, drug costs and patient outcomes such as length of stay and clinical improvement. The time spent on implementing these two strategies will be compared. The study hypothesis is that the preauthorization group will impact on a reduction in antimicrobial cost and utilization, especially in the first 72 hours, when compared to prospective audit. However, patient outcomes will likely be similar. Antimicrobial stewardship programs using preauthorization as a core strategy compared to prospective audit with feedback have similar patient outcomes, but may reduce antimicrobial utilization.

Interventions

OTHERProspective audit strategy of antimicrobial stewardship

applying prospective audit as a different strategy of antimicrobial stewardship

OTHERpreauthorization strategy of antimicrobial stewardship

applying preauthorization as one strategy of antimicrobial stewardship

Sponsors

Kaohsiung Veterans General Hospital.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* In-hospital patients, aged 20 and above, with request from managing physicians for use of restricted antimicrobials.

Exclusion criteria

* Patients admitted to the intensive care unit at evaluation or within 48 hours of entry into the study. * Patients with antimicrobial prescriptions prescribed during after-hours, including weekends and public holidays. * Formal infectious disease consultations requested prior to randomization. * Patients in the emergency department and outpatient department.

Design outcomes

Primary

MeasureTime frameDescription
Antimicrobial utilization using defined daily dose (DDD)4 weeksDefined daily dose (DDD),
Antimicrobial utilization using defined daily dose per 1000 patient days (DID)4 weeksDefined daily dose per 1000 patient days

Secondary

MeasureTime frameDescription
Rate of acceptance to use antimicrobial agents recommended by infectious disease physicians4 weekschoice of antimicrobial agents used matches recommendation by infectious diseases physician
Appropriateness of antimicrobial prescription by susceptibility of culture4 weekscultures shows susceptibility to antimicrobial prescribed

Other

MeasureTime frameDescription
Rate of hospital associated bloodstream infections12 monthsoverall rate of bloodstream infection within the hospital during the study period
Rates of multidrug resistant organisms within the hospital12 monthsRates of carbapenem-resistant Acinetobacter baumanii (CRAB), vancomycin resistant Enterococcus (VRE), Clostridium difficile
30-day mortality30 days post randomizationmortality rate at 30-days post randomization
3-day defervescence rate3 day post randomizationRate of defervescence on day 3 post randomization

Countries

Taiwan

Contacts

Primary ContactSusan Shin-Jung Lee, M.D., Ph.D.
ssjlee28@yahoo.com.tw+886-7-342-2121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026